Does Keytruda Work for Hodgkin Lymphoma?
Yes, Keytruda (pembrolizumab) is FDA-approved to treat certain cases of classical Hodgkin lymphoma (cHL), particularly relapsed or refractory types after at least two prior therapies.[1][2] It targets the PD-1 protein on T-cells, helping the immune system attack cancer cells that exploit this pathway to evade detection—a common issue in cHL tumors with high PD-L1 expression.[3]
How Is Keytruda Used in Hodgkin Lymphoma Treatment?
Keytruda is approved for adults and children with cHL that has relapsed after stem cell transplant or brentuximab vedotin, or if transplant isn't viable. Dosing is typically 200 mg every 3 weeks for adults (or 2 mg/kg for kids), given intravenously for up to 2 years or until disease progression/toxicity.[1] Approval came in 2017 based on KEYNOTE-087 trial data, showing 69% overall response rate (22% complete) in 210 patients.[4]
What Do Clinical Trial Results Show?
In KEYNOTE-087, median progression-free survival was 13.7 months (vs. historical 3-6 months pre-immunotherapy).[4] KEYNOTE-204 compared it directly to brentuximab, with Keytruda extending PFS to 13.2 months vs. 10.9 months (HR 0.65).[5] Long-term follow-up confirms durable responses in about 25-30% of patients.[3] It's not first-line; guidelines place it after chemotherapy like ABVD.
What Side Effects Should Patients Expect?
Common issues include fatigue (40-50%), musculoskeletal pain, diarrhea, rash, and nausea. Serious risks: immune-related events like pneumonitis (lung inflammation, 3-5%), colitis, hepatitis, or endocrinopathies (thyroid/adrenal issues, up to 20%). Infusion reactions occur in 2-5%.[1][2] Monitoring with imaging and labs is standard; steroids treat most immune toxicities.
How Does Keytruda Compare to Other Hodgkin Lymphoma Options?
| Treatment | Role in Relapsed/Refractory cHL | Response Rate | Key Differences |
|-----------|---------------------------------|---------------|-----------------|
| Keytruda | Post-2+ lines; PD-1 inhibitor | 69% ORR [4] | Immune-based; durable in PD-L1+ tumors; outpatient IV |
| Brentuximab vedotin (Adcetris) | Post-1+ lines; antibody-drug conjugate | 75% ORR | Targets CD30; more neuropathy; often pre-Keytruda |
| Nivolumab (Opdivo) | Similar to Keytruda; off-label or trial | 66-87% ORR [6] | Another PD-1 inhibitor; slightly higher thyroid toxicity |
| Chemotherapy (e.g., ICE) | Bridge to transplant | 60-80% short-term | Toxic; not curative alone in refractory cases |
Keytruda edges out brentuximab in PFS for multiply relapsed patients but lacks head-to-head survival data.[5]
When Can Patients Access Keytruda for This?
Approved since March 2017 (accelerated), converted to full in 2020.[1] Covered by Medicare/Medicaid for eligible cases; list price ~$11,000/dose, but financial assistance via Merck cuts out-of-pocket for many.[7] Biosimilars unlikely soon—core PD-1 patent expires 2028, with extensions to 2036+ amid litigation.[8]
What If Keytruda Fails or Isn't Suitable?
Options include clinical trials (e.g., CAR-T like tisa-cel, 70-90% CR in trials), radiation, or salvage chemo/transplant. Not for nodular lymphocyte-predominant HL subtype. Genetic testing for PD-L1 helps predict response.[3]
Sources:
[1] FDA Label: Keytruda Prescribing Information
[2] NCCN Guidelines: Hodgkin Lymphoma v2.2023
[3] NEJM: KEYNOTE-087 Results (2018)
[4] Lancet Oncology: Long-term KEYNOTE-087 (2020)
[5] NEJM: KEYNOTE-204 (2020)
[6] Blood: Nivolumab in cHL (2019)
[7] Merck Pricing: Keytruda Access
[8] DrugPatentWatch: Keytruda Patents